Novartis Pharma AG is an operating company of Novartis AG, a Swiss pharmaceutical group headquartered in Basel. The company discovers, develops, manufactures, and commercializes prescription medicines and biologics, integrating discovery chemistry, process development, and large-scale production.
Its activities span small‑molecule and biologic R&D, active pharmaceutical ingredient (API) and finished‑dose manufacturing, and global supply chain operations. Core therapeutic areas include oncology, immunology, neuroscience, cardiovascular, renal and metabolic diseases, and ophthalmology. Novartis Pharma AG operates research and production sites across Europe, the Americas, and Asia, and collaborates with academic and industry partners for in‑licensing and co‑development.
Following the 2023 spin‑off of Sandoz, the group focuses on innovative pharmaceuticals rather than generics and biosimilars. For chemical industry stakeholders, Novartis Pharma AG is a significant developer and purchaser of advanced intermediates, APIs, and bioprocess technologies, with an emphasis on quality, regulatory compliance, and scalable manufacturing.
Also known as Novartis AG and Novartis International AG.
chemXplore tracks 1 project involving Novartis.
Novartis's role on them: Investor / Financier.
First continuous‑delivery ranibizumab implant for nAMD receives CHMP backing; designed to maintain vision with as few as two refills per year versus monthly injections.
ARVO presentations: real-world Vabysmo data show retinal drying in wet AMD/DME; Susvimo demonstrates sustained delivery and reduced treatment burden; vamikibart shows early efficacy; >45 abstracts
Thomas Biegi, with a strong background in pharma and biotech communications, will succeed Nina Schwab-Hautzinger in April 2026, reporting to Markus Kamieth.
The report highlights 2025 achievements, financials, and 2026 outlook, including revenue growth, strategic acquisitions, and regulatory approvals.
Séverine Lemoine will lead operations in France, focusing on product launches and expanding the local presence in oncology.
Revenue up 21% to $2.66B. Proposed Merus acquisition. FDA priority review for epcoritamab. Rina-S gets Breakthrough Therapy Designation. Operating profit rose to $1.007B.
By country, the most active first. active / all projects
